TY - JOUR
T1 - Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea
AU - Lee, Jin Sol
AU - Shin, Jong Hee
AU - Lee, Kyungwon
AU - Kim, Mi Na
AU - Shia, Bo Moon
AU - Uh, Young
AU - Lee, Wee Gyo
AU - Lee, Hye Soo
AU - Chang, Chulhun L.
AU - Kim, Soo Hyun
AU - Shin, Myung Geun
AU - Suh, Soon Pal
AU - Ryang, Dong Wook
PY - 2007/10
Y1 - 2007/10
N2 - Purpose: The incidence of Candida bloodstream infections (BSI) has increased over the past two decades. The rank order of occurrence and the susceptibility to antifungals of the various Candida species causing BSI are important factors driving the establishment of empirical treatment protocols; however, very limited multi-institutional data are available on Candida bloodstream isolates in Korea. Materiasl and Methods: We investigated the susceptibility to azole antifungals and species distribution of 143 Candida bloodstream isolates recovered from eight university hospitals over a six-month period. Minimal inhibitory concentrations (MICs) of fluconazole, itraconazole, and voriconazole for each isolate were determined by the broth microdilution method of the Clinical and Laboratory Standards Institute (CLSI). Results: The Candida species recovered most frequently from the blood cultures was C albicans (49%), followed by C parapsilosis (22%), C tropicalis (14%), and C. glabrata (11%). The MIC ranges for the Candida isolates were 0.125 to 64 μg/mL, for fluconazole, 0.03 to 2 μg/mL for itraconazole, and 0.03 to 1 μg/mL for voriconazole. Overall, resistance to fluconazole was found in only 2% of the Candida isolates (3/143), while the dose-dependent susceptibility was found in 6% (8/ 143). The resistance and dose-dependent susceptibility of itraconazole were found in 4% (6/143) and 14% (20/143) of the isolates, respectively. All bloodstream isolates were susceptible to voriconazole (MIC,≤ 1 μg/mL). Conclusion: Our findings show that C albicans is the most common cause of Candida-related BSI, followed by C. parapsilosis, and that the rates of resistance to azole antifungals are still low among bloodstream isolates in Korea.
AB - Purpose: The incidence of Candida bloodstream infections (BSI) has increased over the past two decades. The rank order of occurrence and the susceptibility to antifungals of the various Candida species causing BSI are important factors driving the establishment of empirical treatment protocols; however, very limited multi-institutional data are available on Candida bloodstream isolates in Korea. Materiasl and Methods: We investigated the susceptibility to azole antifungals and species distribution of 143 Candida bloodstream isolates recovered from eight university hospitals over a six-month period. Minimal inhibitory concentrations (MICs) of fluconazole, itraconazole, and voriconazole for each isolate were determined by the broth microdilution method of the Clinical and Laboratory Standards Institute (CLSI). Results: The Candida species recovered most frequently from the blood cultures was C albicans (49%), followed by C parapsilosis (22%), C tropicalis (14%), and C. glabrata (11%). The MIC ranges for the Candida isolates were 0.125 to 64 μg/mL, for fluconazole, 0.03 to 2 μg/mL for itraconazole, and 0.03 to 1 μg/mL for voriconazole. Overall, resistance to fluconazole was found in only 2% of the Candida isolates (3/143), while the dose-dependent susceptibility was found in 6% (8/ 143). The resistance and dose-dependent susceptibility of itraconazole were found in 4% (6/143) and 14% (20/143) of the isolates, respectively. All bloodstream isolates were susceptible to voriconazole (MIC,≤ 1 μg/mL). Conclusion: Our findings show that C albicans is the most common cause of Candida-related BSI, followed by C. parapsilosis, and that the rates of resistance to azole antifungals are still low among bloodstream isolates in Korea.
UR - http://www.scopus.com/inward/record.url?scp=36248941920&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36248941920&partnerID=8YFLogxK
U2 - 10.3349/ymj.2007.48.5.779
DO - 10.3349/ymj.2007.48.5.779
M3 - Article
C2 - 17963334
AN - SCOPUS:36248941920
SN - 0513-5796
VL - 48
SP - 779
EP - 786
JO - Yonsei Medical Journal
JF - Yonsei Medical Journal
IS - 5
ER -